Morgan Levine

Morgan Levine developed PhenoAge, a second-generation epigenetic clock trained on mortality-related clinical biomarkers that more accurately captures cancer-relevant biological aging than first-generation clocks. Her research on the convergence of aging and cancer biology through shared epigenetic mechanisms has informed new prevention strategies targeting biological age. She leads cellular reprogramming research at Altos Labs aimed at reversing age-associated cancer risk.